
Norvasc is owned by Viatris Inc. (Nasdaq: VTRS), which acquired the brand in November 2020 when Pfizer spun off its Upjohn division and combined it with Mylan. Norvasc is the brand name for amlodipine, a calcium channel blocker approved by the FDA in July 1992 for hypertension and angina. Originally developed by Pfizer, Norvasc is Viatris's second-largest disclosed product, generating $600 million in net sales in the first nine months of 2026.
Parent Company
Acquired
2020
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Norvasc | Viatris Inc. | Wholly owned |
Pfizer filed its New Drug Application for amlodipine in December 1987, and the FDA approved Norvasc on July 31, 1992, for hypertension, chronic stable angina, and vasospastic angina. The once-daily calcium channel blocker entered a market dominated by older drugs such as Pfizer's own Procardia and offered a smoother side-effect profile and more gradual onset of blood pressure reduction.
Norvasc grew into one of the world's best-selling cardiovascular medicines. Annual sales peaked at approximately $5 billion in the mid-2000s, making it one of the largest prescription drugs of its era. In 2004, the FDA expanded the label to include hypertension in children aged 6 to 17.
The brand's patent position ended early in the United States. An appeals court ruling in favor of generic challenger Apotex allowed generic amlodipine to launch in 2007, and generics rapidly captured most prescription volume. Branded Norvasc continued to sell on the strength of its name, especially in markets where branded products retain a premium.
In November 2020, Norvasc moved to Viatris through the Upjohn and Mylan combination. Under Viatris, branded Norvasc remains commercially significant: it is the company's number two disclosed product behind Lipitor, producing $600.4 million in net sales over the first nine months of 2026. Clinical guidelines from the American Heart Association and the European Society of Cardiology continue to list amlodipine as a first-line treatment option for hypertension.
What does Viatris own?
Viatris owns the Lipitor, Viagra, Xanax, and Eliquis brands, along with a portfolio of over 1,400 approved generic molecules across cardiovascular, respiratory, central nervous system, oncology, immunology, and other therapeutic areas. The company also has a pipeline of complex generics and biosimilars. Its product portfolio was formed through the merger of Upjohn (Pfizer's legacy brand-name drug business) and Mylan (a global generic pharmaceutical company).
Is Viatris publicly traded?
Yes, Viatris Inc. is publicly traded on the Nasdaq stock exchange under ticker VTRS. The company has a dispersed shareholder base with institutional investors holding the majority of shares. Pfizer distributed its Viatris shares to Pfizer shareholders in 2021 and no longer holds a significant ownership stake. Viatris returned more than $1 billion to shareholders in 2025 through share repurchases and dividends.
Who founded Viatris?
Viatris was not founded by individuals. It was created in November 2020 through the merger of Upjohn, a division of Pfizer that held legacy brand-name drugs, and Mylan, a global generic pharmaceutical company founded in 1961 in White Sulphur Springs, West Virginia. The merger combined Upjohn's brand-name portfolio with Mylan's generic manufacturing capabilities to form a new company focused on providing access to affordable medicines.
Where is Viatris headquartered?
Viatris is headquartered in Canonsburg, Pennsylvania, USA. The company maintains its corporate offices in Pennsylvania and operates manufacturing facilities, distribution centers, and sales offices across the world. Its manufacturing network includes facilities in the United States, India, Europe, and China.
How many brands does Viatris own?
Viatris owns four key brand-name medicines: Lipitor, Viagra, Xanax, and Eliquis. The company also owns a portfolio of over 1,400 approved generic molecules across multiple therapeutic areas. In 2025, the company generated approximately $324 million in new product revenues and expects $450 million to $550 million in new product revenues in 2026 from its pipeline of generic and complex generic products.
Who owns Viatris?
Viatris is a publicly traded company with a dispersed shareholder base. Institutional investors, including mutual funds and investment firms, hold the majority of shares. No single shareholder has controlling ownership. Pfizer, the former parent of Upjohn, distributed its Viatris shares to Pfizer shareholders in 2021 and no longer holds a significant stake. The company is governed by a board of directors with independent representation.
What are Viatris's largest brands?
Lipitor and Viagra are Viatris's most recognizable brand-name products. Lipitor is a cholesterol-lowering statin medication originally developed by Pfizer. Viagra is an erectile dysfunction medication also originally developed by Pfizer. Xanax, an anti-anxiety medication, and Eliquis, an anticoagulant, are the company's other major brand-name products. Together, these brands contribute to the Developed Markets segment, which generated $8.5 billion in revenue in 2025.
Early generic entry (2007): A federal appeals court ruling allowed Apotex to launch generic amlodipine ahead of the expected patent expiry, accelerating the branded product's revenue decline in the United States.
Generic formulation variability: In the United Kingdom, different generic suppliers have been documented using different amlodipine salts, including besylate and benzoate forms. Regulators consider the salts medically equivalent, but the variation has drawn scrutiny over interchangeability.
Post-patent pricing: Like all post-patent brands, branded Norvasc sells at a large premium to generic amlodipine in markets where both are available, a pricing structure that attracts periodic criticism from cost-containment advocates.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Bausch Health | Canada | 1987 | Mass market | United states | All Genders | |
| Merck | USA | 1995 | Legacy | United states | All Genders | |
| Viatris | USA | 1996 | Premium | Global | All-ages | |
| Pfizer | USA | 2004 | Mass market | United states | All Genders | |
| Novartis | Switzerland | 2015 | Mass market | Global | All Genders | |
| Sanofi | France | 1997 | Mass market | Global | All Genders |
Healthcare PharmaceuticalsOwned by Bausch Health Companies Inc.
Prescription combination medication for hypertension containing enalapril and hydrochlorothiazide, originally developed by Merck and now distributed by Bausch Health.
Healthcare PharmaceuticalsOwned by Merck & Co.
Prescription blood pressure medication, the first angiotensin II receptor blocker, approved by the FDA in 1995.
Healthcare PharmaceuticalsOwned by Viatris Inc.
Brand name for atorvastatin, the world's best-selling prescription drug from 1996 to 2012, generating over $125 billion in cumulative sales. Originally developed by Parke-Davis and acquired by Pfizer in 2000. Now owned by Viatris Inc. (NASDAQ: VTRS) since November 2020. FY2025 net sales of $1.55 billion.
Healthcare PharmaceuticalsOwned by Pfizer Inc.
Prescription combination drug containing amlodipine and atorvastatin, co-promoted by Pfizer and developed for simultaneous blood pressure and cholesterol management.
Healthcare PharmaceuticalsOwned by Novartis
Prescription cardiovascular medication combining sacubitril and valsartan for treating heart failure, developed and marketed by Novartis. Faced generic competition after July 2025 patent expiry following $7.7 billion in 2025 sales.
Healthcare PharmaceuticalsOwned by Sanofi
Clopidogrel antiplatelet medication co-developed by Sanofi and Bristol-Myers Squibb, FDA approved in 1997, that became the world's second best-selling drug before its patent expired in May 2012.
Market Positioning: Norvasc competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Viatris Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
Band-Aid is privately owned, unlike Norvasc which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
Boots is privately owned, unlike Norvasc which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
Duane Reade is privately owned, unlike Norvasc which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Konsyl Pharmaceuticals Inc.
Psyllium fiber supplement brand produced by Konsyl Pharmaceuticals, a privately held Maryland company marketing the same psyllium active ingredient as Metamucil since 1934.
Konsyl is privately owned, unlike Norvasc which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Kenvue
American brand of ibuprofen pain relief medication owned by Kenvue, the consumer health spinoff from Johnson & Johnson, which is being acquired by Kimberly-Clark in a $40 billion deal announced in November 2025.
Motrin is privately owned, unlike Norvasc which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Kenvue
American brand of over-the-counter first aid antibiotic ointment containing bacitracin, neomycin, and polymyxin B. Owned by Kenvue (NYSE: KVUE) since the August 2023 spin-off from Johnson & Johnson.
Neosporin is privately owned, unlike Norvasc which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.

Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.